Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 3/20 | 0.45 |
| ▸ | PKM | P14618 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 6/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | CRHBP | P24387 | 1/20 | 0.44 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16680963 | 1.00 | ATM (0.45) | ATMHTTPKMMAPTKMT2A | |
| SCHEMBL15544876 | 0.93 | ATM (0.41) | ATMHTTPKMMAPTKMT2A | |
| SCHEMBL15544875 | 0.93 | ATM (0.41) | ATMHTTPKMMAPTKMT2A | |
| SCHEMBL22557892 | 0.81 | PKM (0.47) | HTTPKMMAPTKMT2AMEN1 | |
| SCHEMBL15544893 | 0.79 | ADORA2A (0.42) | KMT2AMEN1ALDH1A1 | |
| SCHEMBL15545354 | 0.79 | ATM (0.43) | ATMHTTMAPTKMT2AMEN1 | |
| SCHEMBL15545351 | 0.79 | ATM (0.43) | ATMHTTMAPTKMT2AMEN1 | |
| SCHEMBL20582641 | 0.76 | HTT (0.53) | HTTPKMMAPTKMT2AMEN1 | |
| SCHEMBL17467143 | 0.75 | CYP2C19 (0.40) | HTTPKMMAPTKMT2AMEN1 | |
| SCHEMBL12469096 | 0.73 | MAPT (0.52) | ATMHTTMAPTKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10316028-B2 | Orexin receptor antagonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2019-06-11 | — | — | US | disclosed |
| US-20180370961-A1 | OREXIN RECEPTOR ANTAGONISTS | NXERA PHARMA UK LIMITED (GB) | 2018-12-27 | — | — | US | disclosed |
| US-9850237-B2 | Orexin receptor antagonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2017-12-26 | — | — | US | disclosed |
| US-20170121320-A1 | OREXIN RECEPTOR ANTAGONISTS | NXERA PHARMA UK LIMITED (GB) | 2017-05-04 | — | — | US | disclosed |
| EP-2870144-B1 | OREXIN RECEPTOR ANTAGONISTS | HEPTARES THERAPEUTICS LTD (GB) | 2017-04-19 | — | — | EP | disclosed |
| US-9555044-B2 | Orexin receptor antagonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2017-01-31 | — | — | US | disclosed |
| US-20160213678-A1 | OREXIN RECEPTOR ANTAGONISTS | NXERA PHARMA UK LIMITED (GB) | 2016-07-28 | — | — | US | disclosed |
| US-20150126498-A1 | OREXIN RECEPTOR ANTAGONISTS | NXERA PHARMA UK LIMITED (GB) | 2015-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170121320-A1 | OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY4R | ATM 4537/4885HTT 628/4885PKM 3680/4885 |
| US-10316028-B2 | Orexin receptor antagonists | HCRTR2, HCRTR1, NPY4R | ATM 4537/4885HTT 628/4885PKM 3680/4885 |
| US-20180370961-A1 | OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY4R | ATM 4537/4885HTT 628/4885PKM 3680/4885 |
| US-20150126498-A1 | OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY4R | ATM 4537/4885HTT 628/4885PKM 3680/4885 |
| US-20160213678-A1 | OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY4R | ATM 4537/4885HTT 628/4885PKM 3680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.